Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 12Prostatic Neoplasms 11Head and Neck Neoplasms 7Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 6Esophageal Neoplasms 5Rectal Neoplasms 4Mouth Neoplasms 4Laryngeal Neoplasms 4Glioma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Papillomavirus Infections 2Oligodendroglioma 2Myelodysplastic Syndromes 2Lymphatic Metastasis 2Leukemia, Myeloid, Acute 2Hypopharyngeal Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Astrocytoma 2Anus Neoplasms 2Virus Diseases 1Vaginal Neoplasms 1

Interventions

fludarabine 1Radiotherapy, Intensity-Modulated 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Camurati-Engelmann Syndrome × Radiotherapy, Intensity-Modulated × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡